Professional sports are no longer having one cannabis conversation. They are having several at once: testing, impairment, pain management, investment, endorsements and athlete business rights. The WNBA and NFL show why those questions need to be separated rather than collapsed into a single claim that a league is either “pro-cannabis” or “anti-cannabis.”
Why start with the collective bargaining agreement?
Because the governing document matters more than a headline. The Women’s National Basketball Players Association publishes the league’s collective bargaining agreement, and its CBA summaries organize provisions including player conduct and discipline.
That is the right place to evaluate what players can actually do. Testing policy, discipline, investment rights and commercial endorsements can sit in different sections and carry different conditions. A league can loosen one restriction without eliminating all the others.
Why do commercial rights matter?
For an active athlete, cannabis policy is not only a question of whether a positive test triggers discipline. It can also determine whether the athlete can invest in a company, lend a name or likeness to a brand, appear in advertising or build a business while still playing.
That distinction matters because retired athletes have built visible cannabis businesses for years. Active athletes operate under collective bargaining agreements, league policies and endorsement restrictions that can narrow what they are permitted to say or sell even when broader cultural attitudes have changed.
What does the NFL comparison show?
The NFL has loosened aspects of its marijuana testing and discipline framework over time while also supporting research into cannabinoids and pain management. Commercial endorsement rules are a separate layer. That produces an environment where health-policy movement does not automatically create unrestricted business rights for active players.
There is nothing inherently contradictory about researching cannabinoids while maintaining commercial restrictions; leagues regulate medical policy and sponsorship categories for different reasons. The sharper question is whether those restrictions remain proportionate as the evidence, law and marketplace evolve.
Where does athlete education fit?
This is where the conversation becomes more useful than league-versus-league scorekeeping. Athletes need to understand the endocannabinoid system, product composition, impairment, league rules, federal and state law, and the commercial restrictions attached to their contracts. A policy change in one category does not eliminate risk in the others.
Beard Bros has covered these conversations with former professional athletes and cannabis operators, including events involving Ricky Williams, Jim McMahon, Calvin Johnson, Adam Jones and Frostee Rucker. Those discussions matter because retired athletes can often speak and build more freely than active players governed by current league rules.
The broader cannabis-and-culture conversation lives in Cannabis Culture, while the business side runs through Cannabis Business.
Source: Beard Bros Pharms, Two Leagues, Two Playbooks: Professional Athletes and Cannabis Business
Frequently Asked Questions
- Why are testing rules and endorsement rules different? Testing and discipline govern player conduct and health-related policy, while endorsement and investment provisions govern commercial activity. A league can change one without changing the other.
- Where should WNBA player rules be verified? The WNBPA publishes the collective bargaining agreement and supporting CBA materials for players and the public.
- Does cannabinoid research automatically mean a league permits cannabis endorsements? No. Research policy and commercial endorsement rules are separate questions.
- Why are retired athletes often more visible in cannabis? They are no longer subject to the same active-player collective bargaining and league commercial restrictions, although ordinary laws and contracts still apply.
- What should athletes understand before entering the cannabis business? League rules, endorsement restrictions, product and impairment science, federal and state law, and the financial structure of any investment or partnership.